Covalent Immobilization of Aldehyde and Alcohol Dehydrogenases on Ordered Mesoporous Silicas

Purpose This work studies the immobilization of two enzymes, the alcohol dehydrogenase (ADH) and the aldehyde dehydrogenase (AldDH) both from Saccharomyces cerevisiae, which could be used to produce high value-added molecules from carboxylic acids embedded in anaerobic digestate.Methods In particular, three mesoporous siliceous materials, with different specific surface areas and pore sizes, (MSU-H, MSU-F and MCF0.75) were used as supports for covalent immobilization. The support materials were characterized by complementary techniques. Then, after a functionalization, creating a covalent bond between the enzyme and the support was performed. The specific activity and immobilization yield of the biocatalysts were then evaluated.Results The best results were obtained with MSU-H and MSU-F, resulting in an immobilization yield greater than 50% in all cases, a specific activity of 0.13 IU/g(supp) with the AldDH/MSU-H, 0.10 IU/g(supp) with AldDH/MSU-F, 48.6 IU/g(supp) with ADH/MSU-H and 12.6 IU/g(supp) with ADH/MSU-H. These biocatalysts were then characterized by optimal pH and temperature and the stability factor was evaluated. With ADH/MSU-F no decrease in activity was observed after 120 h incubated at 50 degrees C. Finally, the biocatalysts AldDH/MSU-H and ADH/MSU-H were used to perform the reduction reaction and it was seen that after five reaction cycles the residual activity was greater than 20% in both cases.Conclusion The ADH and AldDH enzymes have been successfully immobilized on mesoporous siliceous supports, considerably increasing their thermal stability and being able to reuse them for several reaction cycles. The use of this immobilization and these supports is adaptable to a wide variety of enzymes

Cerium‐Copper Oxides Synthesized in a Multi‐Inlet Vortex Reactor as Effective Nanocatalysts for CO and Ethene Oxidation Reactions

In this study, a set of CuCeOx catalysts was prepared via the coprecipitation method using a Multi‐Inlet Vortex Reactor: the Cu wt.% content is 5, 10, 20, 30 and 60. Moreover, pure CeO2 and CuO were synthesized for comparison purposes. The physico‐chemical properties of this set of samples were investigated by complementary techniques, e.g., XRD, N2 physisorption at −196 °C, Scanning Electron Microscopy, XPS, FT‐IR, Raman spectroscopy and H2‐TPR. Then, the CuCeOx catalysts were tested for the CO and ethene oxidation reactions. As a whole, all the prepared samples presented good catalytic performances towards the CO oxidation reaction (1000 ppm CO, 10 vol.% O2/N2): the most promising catalyst was the 20%CuCeOx (complete CO conversion at 125 °C), which exhibited a long‐term thermal stability. Similarly, the oxidative activity of the catalysts were evaluated using a gaseous mixture containing 500 ppm C2H4, 10 vol.% O2/N2. Accordingly, for the ethene oxidation reaction, the 20%CuCeOx catalyst evidenced the best catalytic properties. The elevated catalytic activity towards CO and ethene oxidation was mainly ascribed to synergistic interactions between CeO2 and CuO phases, as well as to the high amount of surface‐chemisorbed oxygen species and structural defects

The anthelmintic praziquantel is a human serotoninergic G-protein-coupled receptor ligand

Schistosomiasis is a debilitating tropical disease caused by infection with parasitic blood flukes. Approximately 260 million people are infected worldwide, underscoring the clinical and socioeconomic impact of this chronic infection. Schistosomiasis is treated with the drug praziquantel (PZQ), which has proved the therapeutic mainstay for over three decades of clinical use. However, the molecular target(s) of PZQ remain undefined. Here we identify a molecular target for the antischistosomal eutomer - (R)-PZQ - which functions as a partial agonist of the human serotoninergic 5HT2B receptor. (R)-PZQ modulation of serotoninergic signaling occurs over a concentration range sufficient to regulate vascular tone of the mesenteric blood vessels where the adult parasites reside within their host. These data establish (R)-PZQ as a G-protein-coupled receptor ligand and suggest that the efficacy of this clinically important anthelmintic is supported by a broad, cross species polypharmacology with PZQ modulating signaling events in both host and parasite

Rapid tests and urine sampling techniques for the diagnosis of urinary tract infection (UTI) in children under five years: a systematic review

Background: Urinary tract infection (UTI) is one of the most common sources of infection in children under five. Prompt diagnosis and treatment is important to reduce the risk of renal scarring. Rapid, cost-effective, methods of UTI diagnosis are required as an alternative to culture. Methods: We conducted a systematic review to determine the diagnostic accuracy of rapid tests for detecting UTI in children under five years of age. Results: The evidence supports the use of dipstick positive for both leukocyte esterase and nitrite (pooled LR+ = 28.2, 95% CI: 17.3, 46.0) or microscopy positive for both pyuria and bacteriuria (pooled LR+ = 37.0, 95% CI: 11.0, 125.9) to rule in UTI. Similarly dipstick negative for both LE and nitrite (Pooled LR- = 0.20, 95% CI: 0.16, 0.26) or microscopy negative for both pyuria and bacteriuria (Pooled LR- = 0.11, 95% CI: 0.05, 0.23) can be used to rule out UTI. A test for glucose showed promise in potty-trained children. However, all studies were over 30 years old. Further evaluation of this test may be useful. Conclusion: Dipstick negative for both LE and nitrite or microscopic analysis negative for both pyuria and bacteriuria of a clean voided urine, bag, or nappy/pad specimen may reasonably be used to rule out UTI. These patients can then reasonably be excluded from further investigation, without the need for confirmatory culture. Similarly, combinations of positive tests could be used to rule in UTI, and trigger further investigation

How does study quality affect the results of a diagnostic meta-analysis?

Background: The use of systematic literature review to inform evidence based practice in diagnostics is rapidly expanding. Although the primary diagnostic literature is extensive, studies are often of low methodological quality or poorly reported. There has been no rigorously evaluated, evidence based tool to assess the methodological quality of diagnostic studies. The primary objective of this study was to determine the extent to which variations in the quality of primary studies impact the results of a diagnostic meta-analysis and whether this differs with diagnostic test type. A secondary objective was to contribute to the evaluation of QUADAS, an evidence-based tool for the assessment of quality in diagnostic accuracy studies. Methods: This study was conducted as part of large systematic review of tests used in the diagnosis and further investigation of urinary tract infection (UTI) in children. All studies included in this review were assessed using QUADAS, an evidence-based tool for the assessment of quality in systematic reviews of diagnostic accuracy studies. The impact of individual components of QUADAS on a summary measure of diagnostic accuracy was investigated using regression analysis. The review divided the diagnosis and further investigation of UTI into the following three clinical stages: diagnosis of UTI, localisation of infection, and further investigation of the UTI. Each stage used different types of diagnostic test, which were considered to involve different quality concerns. Results: Many of the studies included in our review were poorly reported. The proportion of QUADAS items fulfilled was similar for studies in different sections of the review. However, as might be expected, the individual items fulfilled differed between the three clinical stages. Regression analysis found that different items showed a strong association with test performance for the different tests evaluated. These differences were observed both within and between the three clinical stages assessed by the review. The results of regression analyses were also affected by whether or not a weighting (by sample size) was applied. Our analysis was severely limited by the completeness of reporting and the differences between the index tests evaluated and the reference standards used to confirm diagnoses in the primary studies. Few tests were evaluated by sufficient studies to allow meaningful use of meta-analytic pooling and investigation of heterogeneity. This meant that further analysis to investigate heterogeneity could only be undertaken using a subset of studies, and that the findings are open to various interpretations. Conclusion: Further work is needed to investigate the influence of methodological quality on the results of diagnostic meta-analyses. Large data sets of well-reported primary studies are needed to address this question. Without significant improvements in the completeness of reporting of primary studies, progress in this area will be limited

Pembrolizumab as first-line treatment for metastatic uveal melanoma

Background: No standard treatment has been defined for metastatic uveal melanoma (mUM). Although clinical trials testing Nivolumab/Pembrolizumab for cutaneous melanoma did not include mUM, anti PD-1 agents are commonly used for this disease. Patients and methods: In this prospective observational cohort single arm study, we investigated efficacy and safety of Pembrolizumab as first-line therapy for mUM. The efficacy was evaluated in terms of progression-free survival (PFS), response rate and overall survival (OS). Toxicity was also assessed. Results: Seventeen patients were enrolled. A median of 8 cycles were administered (range 2\u201328). Two patients achieved partial response (11.7%), 6 a disease stabilization (35.3%), whereas 9 (53%) had a progression. No complete response was observed. PFS of the overall population was 3.8 months. PFS was 9.7 months for patients with an interval higher than 5 years from diagnosis of primary tumor to metastatic disease and 2.6 months for patients with an interval lower than 5 years [p = 0.039, HR 0.2865 (95% CI 0.0869\u20130.9443)]. Median OS was not reached. The two responding patients were still on treatment with Pembrolizumab at the time of data analysis. Survival was 12.8 months for patients with clinical benefit, while OS for progressive patients was 3.1 months. PD-L1 expression and genomic abnormalities predictive of relapse after diagnosis of primary tumor were not associated with PFS. Toxicity was mild, without grade 3\u20134 side effects. Conclusions: The efficacy of Pembrolizumab does not seem particularly different when compared to other agents for mUM, but responding patients had a remarkable disease control

BepiColombo’s Cruise Phase: Unique Opportunity for Synergistic Observations

The investigation of multi-spacecraft coordinated observations during the cruise phase of BepiColombo (ESA/JAXA) are reported, with a particular emphasis on the recently launched missions, Solar Orbiter (ESA/NASA) and Parker Solar Probe (NASA). Despite some payload constraints, many instruments onboard BepiColombo are operating during its cruise phase simultaneously covering a wide range of heliocentric distances (0.28 AU–0.5 AU). Hence, the various spacecraft configurations and the combined in-situ and remote sensing measurements from the different spacecraft, offer unique opportunities for BepiColombo to be part of these unprecedented multipoint synergistic observations and for potential scientific studies in the inner heliosphere, even before its orbit insertion around Mercury in December 2025. The main goal of this report is to present the coordinated observation opportunities during the cruise phase of BepiColombo (excluding the planetary flybys). We summarize the identified science topics, the operational instruments, the method we have used to identify the windows of opportunity and discuss the planning of joint observations in the future